Analysis of overall survival since clinical diagnosis of malignant ascites for different groups of cancers
| Hazard ratio | Lower limit | Upper limit | P-value | |
|---|---|---|---|---|
| Gynaecological cancers (reference) | - | - | - | 0.06 |
| Hepatobiliary cancers | 1.17 | 0.68 | 2.02 | 0.575 |
| Gastrointestinal cancers | 2.58 | 1.30 | 5.13 | 0.007 |
| Gastrointestinal cancers | 2.58 | 1.30 | 5.13 | 0.007 |
| Breast cancer | 1.42 | 0.73 | 2.74 | 0.299 |
| Rest | 0.71 | 0.25 | 1.99 | 0.511 |
Kaplan-Meier estimates for overall survival since Tenckhoff insertion at specific follow-up times (+95% confidence interval)
| Months since Tenckhoff insertion | % Survival | Lower limit | Upper limit |
|---|---|---|---|
| 3 | 30.0 | 20.9 | 39.6 |
| 6 | 18.0 | 10.8 | 26.8 |
| 12 | 7.7 | 3.2 | 14.5 |
| 18 | 2.6 | 0.3 | 9.9 |
| 24 | 2.6 | 0.3 | 9.9 |
Kaplan-Meier estimates for overall survival since clinical diagnosis of ascites at specific follow-up times (+ 95% confidence interval)
| Months since clinical diagnosis of ascites | % Survival | Lower limit | Upper limit |
|---|---|---|---|
| 3 | 82.2% | 72.6% | 88.7% |
| 6 | 63.2% | 53.3% | 72.2% |
| 12 | 44.7% | 34.1% | 54.7% |
| 18 | 30.6% | 21.2% | 40.4% |
| 24 | 24.7% | 16.2% | 34.1% |
Survival analysis in patients with metastatic ovarian cancer and malignant ascites treated with or without intraperitoneal infusion of catumaxomab after Tenckhoff catheter insertion
| IPCT | Median survival in months | 95% confidence interval | |
|---|---|---|---|
| Lower limit | Upper limit | ||
| With IPCT | 3.22 | 1.61 | 6.58 |
| Without IPCT | 1.61 | 0.69 | 2.40 |
Type of primary cancer
| Primary malignant disease | Statistic | All |
|---|---|---|
| Gynaecological cancer | n/N (%) | 41/94 (43.6%) |
| Ovarian cancer | n/N | 38/94 |
| Endometrial cancer | n/N | 3/94 |
| Hepatobiliary cancer | n/N (%) | 24/94 (25.5%) |
| Pancreatic cancer | n/N | 11/94 |
| Cholangiocarcinoma | n/N | 12/94 |
| Hepatocellular carcinoma | n/N | 1/94 |
| Gastrointestinal cancer | n/N (%) | 11/94 (11.7%) |
| Colorectal cancer | n/N | 6/94 |
| Gastric cancer | n/N | 3/94 |
| Small bowel neuroendocrine cancer | n/N | 2/94 |
| Breast cancer | n/N (%) | 13/94 (13.8%) |
| Rest | n/N (%) | 5/94 (5.3%) |
Paracenteses prior to Tenckhoff catheter placement
| Number of paracenteses | Statistic | All |
|---|---|---|
| 0 | n/N (%) | 19/94 (20.2%) |
| 1 | n/N (%) | 20/94 (21.3%) |
| 2 | n/N (%) | 16/94 (17.0%) |
| 3 | n/N (%) | 15/94 (16.0%) |
| 4 or > 4 | n/N (%) | 24/94 (25.5%) |